Abstract
Elicitation of potent and broadly neutralizing antibodies is an important goal in designing an effective human immunodeficiency virus-1 (HIV-1) vaccine. The HIV-1 gp41 inner-core trimer represents a functionally and structurally conserved target for therapeutics. Here we report the 2.0-Å-resolution crystal structure of the complex between the antigen-binding fragment of D5, an HIV-1 cross-neutralizing antibody, and 5-helix, a gp41 inner-core mimetic. Both binding and neutralization depend on residues in the D5 CDR H2 loop protruding into the conserved gp41 hydrophobic pocket, as well as a large pocket in D5 surrounding core gp41 residues. Kinetic analysis of D5 mutants with perturbed D5-gp41 interactions suggests that D5 persistence at the fusion intermediate is crucial for neutralization. Thus, our data validate the gp41 N-peptide trimer fusion intermediate as a target for neutralizing antibodies and provide a template for identification of more potent and broadly neutralizing molecules.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Burton, D.R. et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5, 233–236 (2004).
Wyatt, R. & Sodroski, J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280, 1884–1888 (1998).
Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307–312 (2003).
Kwong, P.D. et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678–682 (2002).
Poignard, P., Saphire, E.O., Parren, P.W. & Burton, D.R. gp120: biologic aspects of structural features. Annu. Rev. Immunol. 19, 253–274 (2001).
Zwick, M.B., Saphire, E.O. & Burton, D.R. gp41: HIV's shy protein. Nat. Med. 10, 133–134 (2004).
Burton, D.R., Stanfield, R.L. & Wilson, I.A. Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. USA 102, 14943–14948 (2005).
Calarese, D.A. et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300, 2065–2071 (2003).
Saphire, E.O. et al. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293, 1155–1159 (2001).
Stanfield, R.L., Gorny, M.K., Williams, C., Zolla-Pazner, S. & Wilson, I.A. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447–52D. Structure 12, 193–204 (2004).
Thali, M. et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120–CD4 binding. J. Virol. 67, 3978–3988 (1993).
Labrijn, A.F. et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77, 10557–10565 (2003).
Conley, A.J. et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41–2F5, an anti-gp41 human monoclonal antibody. Proc. Natl. Acad. Sci. USA 91, 3348–3352 (1994).
Zwick, M.B. et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75, 10892–10905 (2001).
Zwick, M.B. et al. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J. Virol. 78, 3155–3161 (2004).
Baba, T.W. et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6, 200–206 (2000).
Mascola, J.R. et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6, 207–210 (2000).
Veazey, R.S. et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9, 343–346 (2003).
Mascola, J.R. et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73, 4009–4018 (1999).
Trkola, A. et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11, 615–622 (2005).
Tan, K., Liu, J., Wang, J., Shen, S. & Lu, M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. USA 94, 12303–12308 (1997).
Weissenhorn, W., Dessen, A., Harrison, S.C., Skehel, J.J. & Wiley, D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426–430 (1997).
Chan, D.C., Fass, D., Berger, J.M. & Kim, P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263–273 (1997).
Furuta, R.A., Wild, C.T., Weng, Y. & Weiss, C.D. Capture of an early fusion-active conformation of HIV-1 gp41. Nat. Struct. Biol. 5, 276–279 (1998).
Wild, C., Oas, T., McDanal, C., Bolognesi, D. & Matthews, T. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. USA 89, 10537–10541 (1992).
Ferrer, M. et al. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat. Struct. Biol. 6, 953–960 (1999).
Eckert, D.M., Malashkevich, V.N., Hong, L.H., Carr, P.A. & Kim, P.S. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99, 103–115 (1999).
Lalezari, J.P. et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348, 2175–2185 (2003).
Sanders, R.W., Korber, B., Lu, M., Berkhout, B. & Moore, J.P. Mutational analyses and natural variability of the gp41 ectodomain. in HIV Sequence Compendium (eds. Kuiken C. et al.) 43–68 (Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, USA, 2002).
Hamburger, A.E., Kim, S., Welch, B.D. & Kay, M.S. Steric accessibility of the HIV-1 gp41 N-trimer region. J. Biol. Chem. 280, 12567–12572 (2005).
Louis, J.M., Nesheiwat, I., Chang, L., Clore, G.M. & Bewley, C.A. Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J. Biol. Chem. 278, 20278–20285 (2003).
Miller, M.D. et al. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc. Natl. Acad. Sci. USA 102, 14759–14764 (2005).
Root, M.J., Kay, M.S. & Kim, P.S. Protein design of an HIV-1 entry inhibitor. Science 291, 884–888 (2001).
Eckert, D.M. & Kim, P.S. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc. Natl. Acad. Sci. USA 98, 11187–11192 (2001).
Al-Lazikani, B., Lesk, A.M. & Chothia, C. Standard conformations for the canonical structures of immunoglobulins. J. Mol. Biol. 273, 927–948 (1997).
Sundberg, E.J. & Mariuzza, R.A. Molecular recognition in antibody-antigen complexes. Adv. Protein Chem. 61, 119–160 (2002).
Lawrence, M.C. & Colman, P.M. Shape complementarity at protein/protein interfaces. J. Mol. Biol. 234, 946–950 (1993).
Davies, D.R. & Cohen, G.H. Interactions of protein antigens with antibodies. Proc. Natl. Acad. Sci. USA 93, 7–12 (1996).
Zhou, G. et al. The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core. Bioorg. Med. Chem. 8, 2219–2227 (2000).
Huang, C.C. et al. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc. Natl. Acad. Sci. USA 101, 2706–2711 (2004).
Yang, X., Kurteva, S., Lee, S. & Sodroski, J. Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. J. Virol. 79, 3500–3508 (2005).
Zhang, M.Y. et al. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J. Virol. 78, 9233–9242 (2004).
Munoz-Barroso, I., Durell, S., Sakaguchi, K., Appella, E. & Blumenthal, R. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J. Cell Biol. 140, 315–323 (1998).
Selzer, T., Albeck, S. & Schreiber, G. Rational design of faster associating and tighter binding protein complexes. Nat. Struct. Biol. 7, 537–541 (2000).
MacCallum, R.M., Martin, A.C. & Thornton, J.M. Antibody-antigen interactions: contact analysis and binding site topography. J. Mol. Biol. 262, 732–745 (1996).
Lobo, E.D., Hansen, R.J. & Balthasar, J.P. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93, 2645–2668 (2004).
Li, A. et al. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res. Hum. Retroviruses 13, 647–656 (1997).
Bianchi, E. et al. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc. Natl. Acad. Sci. USA 102, 12903–12908 (2005).
Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760–763 (1994).
Perrakis, A., Morris, R. & Lamzin, V.S. Automated protein model building combined with iterative structure refinement. Nat. Struct. Biol. 6, 458–463 (1999).
Acknowledgements
Help with data collection from the European Synchrotron Radiation Facility staff and the technical assistance and discussions of members of the Carfí laboratory are greatly appreciated. We also thank B. Chen and M. Bottomley for critically reading the manuscript and M. Emili for help with the artwork. SEC-MALS analysis was performed at the W.M. Keck Foundation Biotechnology Resource Laboratory at Yale University. M.L. is the recipient of a European Molecular Biology Organization Postdoctoral Fellowship.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Several authors of this paper are current or former employees of Merck & Co., Inc.
Supplementary information
Supplementary Fig. 1
Representative electron density. (PDF 272 kb)
Supplementary Fig. 2
D5 CDR H2 insertion into gp41 hydrophobic pocket. (PDF 58 kb)
Supplementary Fig. 3
D5 Fab binding around the gp41 N-peptide trimer. (PDF 60 kb)
Supplementary Table 1
Characterization of D5 CDR loops. (PDF 21 kb)
Supplementary Table 2
Buried surfaces in D5–5-helix and other gp41 inner core complexes. (PDF 11 kb)
Rights and permissions
About this article
Cite this article
Luftig, M., Mattu, M., Di Giovine, P. et al. Structural basis for HIV-1 neutralization by a gp41 fusion intermediate–directed antibody. Nat Struct Mol Biol 13, 740–747 (2006). https://doi.org/10.1038/nsmb1127
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nsmb1127
This article is cited by
-
Potential neutralizing antibodies discovered for novel corona virus using machine learning
Scientific Reports (2021)
-
Statistical inference of a convergent antibody repertoire response to influenza vaccine
Genome Medicine (2016)
-
Novel neutralising antibodies targeting the N-terminal helical region of the transmembrane envelope protein p15E of the porcine endogenous retrovirus (PERV)
Immunologic Research (2014)
-
Structure and immune recognition of trimeric pre-fusion HIV-1 Env
Nature (2014)
-
Side chain requirements for affinity and specificity in D5, an HIV-1 antibody derived from the VH1-69 germline segment
BMC Biochemistry (2013)